OATD-01
Sponsors
Molecure S.A.
Conditions
Active Pulmonary SarcoidosisPulmonary Sarcoidosis
Phase 2
Efficacy and Safety Study of OATD-01 in Patients With Active Pulmonary Sarcoidosis
RecruitingNCT06205121
Start: 2024-03-21End: 2027-09-01Target: 96Updated: 2026-07-30
A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase-1 (CHIT1), for the treatment of active pulmonary sarcoidosis (the KITE study)
WithdrawnCTIS2023-506642-23-00
Target: 72Updated: 2024-01-22
A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of a 12-week administration of OATD-01, an oral inhibitor of chitinase-1 (CHIT1), for the treatment of active pulmonary sarcoidosis (the KITE study)
RecruitingCTIS2023-506642-23-01
Start: 2024-08-28Target: 71Updated: 2025-11-06